International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 2 , Pages 345-351 , 1 February 2001

The translational research chain: is it delivering the goods?

Presented at ICTR 2000, Lugano, Switzerland, March 5–8, 2000.

  • Michael Baumann, M.D., Ph.D.

      Affiliations

    • Department of Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Dresden, Dresden, Germany
    • Corresponding Author InformationReprint requests to: Dr. Michael Baumann, Department of Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Dresden, Fetscherstr. 74, 01307 Dresden, Germany
    • ,
  • Søren M Bentzen, Ph.D. (D.Sc.)

      Affiliations

    • Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    • ,
  • Wolfgang Doerr, Ph.D. (D.V.M.)

      Affiliations

    • Department of Radiotherapy and Radiation Oncology, Medical Faculty Carl Gustav Carus, University of Dresden, Dresden, Germany
    • ,
  • Michael C Joiner, Ph.D.

      Affiliations

    • Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    • ,
  • Michele Saunders, M.D.

      Affiliations

    • Marie Curie Research Wing, Mount Vernon Hospital, Northwood, Middlesex, United Kingdom
    • ,
  • Ian F Tannock, M.D., Ph.D.

      Affiliations

    • Princess Margaret Hospital and University of Toronto, Toronto, Canada
    • ,
  • Howard D Thames, Ph.D.

      Affiliations

    • Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, TX, USA

,Accepted 31 August 2000.

References 

  1. Saunders M, Dische S, Barrett A, et al.  Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer (A randomised multicentre trial). Lancet. 1997;350:161–165
  2. Brown JM, Siim BG. Hypoxia specific cytotoxins in cancer therapy. Semin Radiat Oncol. 1996;6:22–36
  3. Overgaard J, Horsman MR. Modification of hypoxia-induced radioresistence in tumors by the use of oxygen and sensitizers. Semin Radiat Oncol. 1996;6:10–21
  4. Komaki R. Combined chemotherapy and radiation therapy in surgically unresectable regionally advanced non-small cell lung cancer. Semin Radiat Oncol. 1996;6:86–91
  5. Brizel DM. Radiotherapy and concurrent chemotherapy for the treatment of locally advanced head and neck squamous cell carcinoma. Semin Radiat Oncol. 1998;8:237–246
  6. Thomas GM. Concurrent chemotherapy and radiation for locally advanced cervical cancer (The new standard of care). Semin Radiat Oncol. 2000;10:44–50
  7. O’Reilly MS, Boehm T, Shing Y, et al.  Endostatin (An endogenous inhibitor of angiogenesis and tumor growth). Cell. 1997;88:277–285
  8. Milas L, Mason K, Hunter N, et al.  In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 2000;6:701–708
  9. Stewart FA, Soranson JA, Alpen EL, et al.  Radiation-induced renal damage (The effects of hyperfractionation). Radiat Res. 1984;98:407–420
  10. Travis EL, Thames HD, Watkins TL, et al.  The kinetics of repair in mouse lung after fractionated irradiation. Int J Radiat Biol Relat Stud Phys Chem Med. 1987;52:903–919
  11. Williams WV, Denekamp J, Fowler JF. A review of α/β ratios for experimental tumours (Implications for clinical studies on altered fractionation). Int J Radiat Oncol Biol Phys. 1985;11:87–96
  12. Petersen C, Baumann M, Dubben HH, et al.  Linear–quadratic analysis of tumour response to fractionated radiotherapy (A study on human squamous cell carcinoma xenografts). Int J Radiat Biol. 1997;73:197–205
  13. Dörr W. Three A’s of normal tissue repopulation. A review of mechanisms. Int J Radiat Biol. 1997;72:635–644
  14. Baumann M, Petersen C, Schulz P, et al.  Impact of overall treatment time on local control of slow growing human GL squamous cell carcinoma in nude mice treated by fractionated irradiation. Radiother Oncol. 1999;50:107–111
  15. Hopewell JW. The volume effect in radiotherapy—Its biological significance. Br J Radiol. 1997;70:S32–S40
  16. Stewart FA. Re-treatment after full-course radiotherapy (Is it a viable option?). Acta Oncol. 1999;38:855–862
  17. Janvier R, Sourla A, Koutsilieris M, et al.  Stromal fibroblasts are required for PC-3 human prostate cancer cells to produce capillary-like formation of endothelial cells in a three-dimensional co-culture system. Anticancer Res. 1997;17:1551–1557
  18. Bernhard EJ, McKenna WG, Hamilton AD, et al.  Inhibiting Ras prenylation increases the radiosensitivity of human tumor cell lines with activating mutations of ras oncogenes. Cancer Res. 1998;58:1754–1761
  19. Taghian AG, Suit HD. Animal systems for translational research in radiation oncology. Acta Oncol. 1999;38:829–838
  20. Rockwell S. Experimental radiotherapy (A brief history). Radiat Res. 1998;150:S157–S169
  21. Kallman RF. Some aspects of the time-dose-relationship in spontaneous and transplanted mouse tumors irradiated in vivo. In: Research in radiotherapy, approaches to chemical sensitization. Report No. 35. Washington, DC: National Academy of Sciences, 1961.
  22. Suit HD, Shalek RJ. Response of spontaneous mammary carcinoma of the C3H mouse to x-irradiation given under conditions of local tissue anoxia. J Natl Cancer Inst. 1963;31:497–509
  23. Gillette EL. Hyperthermia effects in animals with spontaneous tumors. National Cancer Institute monograph 61: 3rd International Symposium Cancer Therapy Hyperthermia, Drugs and Radiation. NIH publication no. 82-2437. Washington, DC: US Government Printing Office; 1982. p. 361–364.
  24. Ang KK, Price RE, Stephens LC, et al.  The tolerance of primate cord to re-irradiation. Int J Radiat Oncol Biol Phys. 1993;25:459–464
  25. Knudson AG, Hethcote HW, Brown BW. Mutation and childhood cancer (A probabilistic model for the incidence of retinoblastoma). Proc Natl Acad Sci USA. 1975;72:5116–5120
  26. Luria SE, Delbruck M. Mutations of bacteria from virus sensitivity to virus resistance. Genetics. 1943;28:491–511
  27. Mack W, Langholz B, Thomas DC. Survival models for familial aggregation of cancer. Environ Health Perspect. 1990;87:27–35
  28. Peng Y, Dear KGB, Denham JW. A generalized F-mixture model for cure rate estimation. Stat Med. 1998;17:813–830
  29. Schwartz D, Flamant R, Lellouch J. Clinical trials. London: Academic Press; 1980;
  30. Weijer C, Freedman B, Fuks A, et al.  What difference does it make to be treated in a clinical trial? A pilot study. Clin Invest Med. 1996;19:179–183
  31. Bentzen SM. Towards evidence based radiation oncology (Improving the design, analysis, and reporting of clinical outcome studies in radiotherapy). Radiother Oncol. 1998;46:5–18
  32. Ellis F. Dose, time and fractionation (A clinical hypothesis). Clin Radiol. 1969;20:1–7
  33. Fowler JF, Morgan MA, Silvester JA, et al.  Experiments with fractionated X-ray treatment of the skin of pigs. I. Fractionation up to 28 days. Br J Radiol. 1963;36:188–196
  34. Bentzen SM, Overgaard J. Time–dose relationships in radiotherapy. In:  Steel GG editors. Basic clinical radiobiology. London: Arnold; 1997;p. 98–105
  35. Withers HR, Thames HD, Flow BL, Mason KA, Hussey DH. The relationship of acute and late skin injury in 2 and 5 fraction/week (γ-ray therapy). Int J Radiat Oncol Biol Phys. 1978;4:595–601
  36. Thames HD, Withers HR, Peters LJ, et al.  Changes in early and late radiation responses with altered dose fractionation (Implications for dose–survival relationships). Int J Radiat Oncol Biol Phys. 1982;8:219–226
  37. Withers HR, Peters LJ, Thames HD, et al.  Hyperfractionation. Int J Radiat Oncol Biol Phys. 1982;8:1807–1809
  38. Horiot JC, Le Fur R, N′Guyen T, et al.  Hyperfractionation versus conventional fractionation in oropharyngeal carcinoma (Final analysis of a randomized trial of the EORTC cooperative group of radiotherapy). Radiother Oncol. 1992;25:231–241
  39. Thames HD. Effect-independent measures of tissue responses to fractionated irradiation. Int J Radiat Oncol Biol Phys. 1984;45:1–10
  40. Thames HD, Withers HR, Peters LJ. Tissue repair capacity and repair kinetics deduced from multifractionated or continuous irradiation regimens with incomplete repair. Br J Cancer. 1984;49(Suppl. VI):263–269
  41. Ang KK, Jiang GL, Guttenberger R, et al.  Impact of spinal cord repair kinetics on the practice of altered fractionation schedules. Radiother Oncol. 1992;25:287–294
  42. Bentzen SM, Saunders MI, Dische S. Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer. Radiother Oncol. 1999;53:219–226
  43. Joiner MC, Marples B, Lambin P; et al. Low-dose hypersensitivity: current status and possible mechanisms. Proceedings of ICTR 2000, Lugano, Switzerland. Int J Radiat Oncol Biology Phys 2000 In press.
  44. Hermans AF, Barendsen GW. Changes of cell proliferation characteristics in a rat rhabdomyosarcoma before and after x-irradiation. Eur J Cancer. 1969;5:173–189
  45. Suit HD, Howes AE, Hunter N. Dependence of response of a C3H mammary carcinoma to fractionated irradiation on fraction number and intertreatment interval. Radiat Res. 1977;72:440–454
  46. Withers HR, Taylor JMG, Maciejewski B. The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol. 1988;27:131–146
  47. Overgaard J, Sand Hansen H, Sapru W, et al.  Conventional radiotherapy as the primary treatment of squamous cell carcinoma (SCC) of the head and neck. A randomized multicenter study of 5 versus 6 fractions per week—Preliminary report from the DAHANCA 6 and 7 trial (Abstr.). Radiother Oncol. 1996;40:S31
  48. Horiot JC, Bontemps P, Van den Bogart W, et al.  Accelerated fractionation (AF) compared to conventional fractionation (CF) improves loco-regional control in the radiotherapy of advanced head and neck cancers (Results of the EORTC 22851 randomized trial). Radiother Oncol. 1997;44:111–121
  49. Dische S, Saunders M, Barrett A, et al.  A randomised multicentre trial of CHART versus conventional radiotherapy in head and neck cancer. Radiother Oncol. 1997;44:123–136
  50. Fu KK, Pajak TF, Trotti A, et al.  A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas (First report of RTOG 9003). Int J Radiat Oncol Biol Phys. 2000;48:7–16
  51. Ball D, Bishop J, Smith J, et al.  A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer (Final report of an Australian multi-centre trial). Radiother Oncol. 1999;52:129–136
  52. Baumann M. Accelerated radiation therapy in non-small cell lung cancer. Radiother Oncol. 1999;52:97–99
  53. Begg AC, Haustermans K, Hart AAM, et al.  The value of pretreatment cell kinetic parameters as predictors for radiotherapy outcome in head and neck cancer (A multicenter analysis). Radiother Oncol. 1999;50:13–23
  54. Board of Faculty of Clinical Oncology, The Royal College of Radiologists. Guidelines for the management of the unscheduled interruption or prolongation of a radical course of radiotherapy. Roy Coll Radiologists Lond 1996.
  55. Huang SM, Bock JM, Harari PM. Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinoma of the head and neck. Cancer Res. 1999;59:1935–1949

☆ This work has been supported in part by the Deutsche Forschungsgemeinschaft, the Cancer Research Campaign, The National Cancer Institute of Canada, and the Gray Laboratory Cancer Research Trust.

PII: S0360-3016(00)01483-8

International Journal of Radiation Oncology * Biology * Physics
Volume 49, Issue 2 , Pages 345-351 , 1 February 2001

Article Tools

* Image Usage & Resolution